Novel strategies for the pharmacological management of type 2 diabetes
| Autor: | Arash Nourparvar, Angela Bulotta, Umberto Di Mario, Riccardo Perfetti |
|---|---|
| Rok vydání: | 2004 |
| Předmět: |
medicine.medical_specialty
medicine.medical_treatment Receptors Cytoplasmic and Nuclear Type 2 diabetes Disease Toxicology Bioinformatics Glucagon-Like Peptide 1 Internal medicine Diabetes mellitus medicine Humans Hypoglycemic Agents Insulin Myocardial infarction Protein Precursors Stroke Pharmacology business.industry Glucagon medicine.disease Peptide Fragments Sulfonylurea Compounds medicine.anatomical_structure Endocrinology Diabetes Mellitus Type 2 Mechanism of action medicine.symptom Pancreas business Transcription Factors |
| Zdroj: | Trends in Pharmacological Sciences. 25:86-91 |
| ISSN: | 0165-6147 |
| Popis: | Type 2 diabetes is characterized by high concentrations of glucose in the blood, which is caused by decreased secretion of insulin from the pancreas and decreased insulin action. This condition is prevalent worldwide and is associated with morbidity and mortality secondary to complications such as myocardial infarction, stroke and end-stage renal disease. The importance of tight control of blood glucose in either preventing or delaying the progression of complications is recognized. Currently, there are many therapeutic options to treat hyperglycemia in type 2 diabetes. However, tight control is difficult to achieve and is often associated with side-effects. Recent advances in understanding insulin secretion, action and signaling have led to the development of new pharmacological agents. In this article, we review new molecules that are promising candidates for the future management of diabetes, focusing on their mechanism of action, efficacy, safety profile and potential benefits compared with pharmacological agents that are available currently. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect